DURECT Corporation  

(Public, NASDAQ:DRRX)   Watch this stock  
Find more results for DRRX
1.51
-0.03 (-1.95%)
Sep 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.50 - 1.57
52 week 1.20 - 2.69
Open 1.55
Vol / Avg. 0.00/252,295.00
Mkt cap 168.51M
P/E     -
Div/yield     -
EPS -0.19
Shares 111.60M
Beta 1.34
Inst. own 44%
Nov 3, 2014
Q3 2014 DURECT Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 10, 2014
DURECT Corporation at Rodman & Renshaw Global Investment Conference - Webcast
Aug 7, 2014
Q2 2014 DURECT Corp Earnings Call - Webcast
Aug 7, 2014
Q2 2014 DURECT Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -119.58% -139.97%
Operating margin -118.93% -138.08%
EBITD margin - -134.44%
Return on average assets -48.07% -49.45%
Return on average equity -80.29% -63.99%
Employees 101 -
CDP Score - -

Address

10260 Bubb Road
CUPERTINO, CA 95014-4166
United States - Map
+1-408-7771417 (Phone)
+1-408-7773577 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company�s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company�s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.

Officers and directors

Felix Theeuwes DSc Chairman, Chief Scientific Officer
Age: 76
Bio & Compensation  - Reuters
James E. Brown DVM President, Chief Executive Officer and Director
Age: 57
Bio & Compensation  - Reuters
Matthew J. Hogan Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Su Il Il Yum Ph.D. Executive Vice President - Pharmaceutical Systems Research and Development
Age: 73
Bio & Compensation  - Reuters
Judy Joice Senior Vice President - Operations and Corporate Quality Assurance
Age: 57
Bio & Compensation  - Reuters
David R. Hoffmann Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 69
Bio & Compensation  - Reuters
Terrence F. Blaschke M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Armand P. Neukermans Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Jon S. Saxe Independent Director
Age: 77
Bio & Compensation  - Reuters